However, patients vary in their response to chemotherapy drugs and side effects, so the therapeutic effect and safety are significantly different.2 With the continuous progress of gene technology, benefits are obtained from targeted drugs by an increasing number of patients with advanced NSCLC.3 Certain gene tests, such as XPG gene testing, may be used as predictors of individualized NSCLC treatment strategies.4 Currently, PD-1/PDL-1 monoclonal antibody is widely used in the treatment of lung cancer. Here, CD274 is linked to non-small cell lung carcinoma.